Andrew McConaghie

The triple-G agonist should help Eli Lilly carve out a new segment in the high BMI obesity market, but its low dose may also compete with established rivals.

Hoping to gain a first approval for CagriSema later this year, Novo wants to squeeze out more efficacy from its amylins with further studies of the combination and of its next-generation asset.

The acquisition brings two potential best-in-class assets which GSK will add to its existing presence in targeted lung cancer therapy.

AstraZeneca is moving its GLP-1 agonist contender, elecoglipron, into Phase III trials which include cardiovascular drugs combinations, in the hope that it can unlock a huge global market.

Beating Zepbound's weight loss with its GLP-1/GIP asset enicepatide may not be enough – leading with its amylin asset petrelintide or a combination may be the best strategy for the Swiss company.

Already a leader in traditional CAR-Ts, Legend is moving fast with its in vivo platform.

Participants are quitting placebo arms of obesity studies or seeking out commercially available GLP-1 drugs while staying on the trial, causing problems for developers hoping to catch up with the frontrunners.

Roche has bought into Nurix's strong BTK degrader competitor, bexobrutideg, but BeOne will be first with a pivotal readout for its candidate, tacabrutideg, in this burgeoning drug class.

The US headquartered firm is using a China-based clinical trial to pioneer its extracellular vesicle in the muscle-wasting disease, Duchenne muscular dystrophy.

The US-China company is looking to challenge Foundayo and other weight loss pills with CX11 and its improved tolerability, with encouraging Phase II results